About Myonexus Therapeutics
Myonexus Therapeutics is a company based in Columbus (United States) founded in 2017 by Michael Triplett was acquired by Sarepta in May 2018. Myonexus Therapeutics has raised $2.5 million across 1 funding round from investors including Sarepta Therapeutics, CincyTech and Rev1 Ventures. Myonexus Therapeutics operates in a competitive market with competitors including Insitro, BridgeBio, ATAI, Forge Biologics and Spark Therapeutics, among others.
- Headquarter Columbus, United States
- Founders Michael Triplett
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$2.5 M (USD)
in 1 rounds
-
Latest Funding Round
$2.5 M (USD), Seed
Dec 13, 2017
-
Investors
Sarepta Therapeutics
& 4 more
-
Employee Count
Not available
-
Acquired by
Sarepta
(May 03, 2018)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Myonexus Therapeutics
Myonexus Therapeutics has successfully raised a total of $2.5M through 1 strategic funding round. The most recent funding activity was a Seed round of $2.5 million completed in December 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Myonexus Therapeutics
Myonexus Therapeutics has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include Sarepta Therapeutics, CincyTech and Rev1 Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
CincyTech is engaged in venture capital investments for innovative startups.
|
Locked | Locked | Locked | |
|
Startup Studio building companies in the US & Europe and Angel Network for Ohio based companies
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked |
Investor details for Myonexus Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Myonexus Therapeutics
Investment portfolio details for Myonexus Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Myonexus Therapeutics
Detailed financials for Myonexus Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Myonexus Therapeutics Comparisons
Peer comparison for Myonexus Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Myonexus Therapeutics
Myonexus Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Insitro, BridgeBio, ATAI, Forge Biologics and Spark Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
An AI-enabled platform is developed for infectious disease treatment.
|
|
| Locked | Locked | Locked |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| Locked | Locked | Locked |
A biopharmaceutical company accelerating innovative mental health treatments.
|
|
| Locked | Locked | Locked |
Gene therapies for rare diseases are developed to treat patients.
|
|
| Locked | Locked | Locked |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| Locked | Locked | Locked |
Provider of cell therapies to treat cancer and hematologic conditions
|
Detailed competitors of Myonexus Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Myonexus Therapeutics
Complete news archive for Myonexus Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Myonexus Therapeutics
Myonexus Therapeutics was founded in 2017.
Myonexus Therapeutics is headquartered in Columbus, United States. It is registered at Columbus, Ohio, United States.
Michael Triplett is the current CEO of Myonexus Therapeutics. They have also founded this company.
Myonexus Therapeutics is a funded company, having raised a total of $2.5M across 1 funding round to date.
Myonexus Therapeutics was founded in 2017 in Columbus, United States, focusing on the gene therapy sector. Treatments for Limb-girdle muscular dystrophy types 2D, 2B, 2E, 2L, and 2C are being advanced, with research based at Nationwide Childrens Hospital. The lead candidate MYO-102, targeting alpha-sarcoglycan for LGMD2D, is in Phase 12a trials. FDA approval has been granted for Phase 12a trials of MYO-101 for LGMD2E via systemic IV delivery.
Myonexus Therapeutics's top competitors include Spark Therapeutics, BridgeBio and Forge Biologics.
Myonexus Therapeutics has 5 investors. Key investors include Sarepta Therapeutics, CincyTech, Rev1 Ventures, Jain Foundation, and Gfbonlus.